Related Experiment Videos
Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal
1Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston.
Seminars in Surgical Oncology
|January 1, 1988
Summary
Adjuvant chemotherapy shows no overall survival benefit in adult soft-tissue sarcoma. While some studies suggest advantages for extremity tumors, it remains investigational for most cases.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Adjuvant chemotherapy is standard for pediatric sarcomas like osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
- Its role in adult soft-tissue sarcoma (aSSTS) remains controversial due to varying study designs and outcomes.
- Focusing on randomized trials with non-treatment control arms is crucial for reliable analysis.
Purpose of the Study:
- To analyze the efficacy of adjuvant chemotherapy in adult soft-tissue sarcoma.
- To evaluate survival outcomes based on tumor location (extremity vs. central body).
- To determine if adjuvant chemotherapy should be considered standard care or investigational for aSSTS.
Main Methods:
- Systematic review and analysis of 11 reported adjuvant chemotherapy studies in adult soft-tissue sarcoma.
- Inclusion criteria focused on randomized studies with non-treatment control arms.
- Outcomes assessed included overall survival and disease-free survival.
Main Results:
- None of the 11 studies demonstrated a significant overall survival advantage for adjuvant chemotherapy.
- Subset analysis indicated a potential survival and disease-free survival benefit for extremity primary tumors.
- No significant survival advantage was observed for central body lesions.
Conclusions:
- Adjuvant chemotherapy does not provide an overall survival benefit for adult soft-tissue sarcoma.
- While promising for extremity primaries, further research is needed.
- Adjuvant chemotherapy should be considered investigational for adult soft-tissue sarcomas.